Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

  • Multiple Sclerosis (MS)
Trial Status:

Recruiting

This trial runs in
Cities
  • Atlanta
  • Baltimore
  • Chicago
  • Dallas
  • Dayton
  • Detroit
  • Greensboro
  • Guaynabo
  • Hackensack
  • Indianapolis
  • Los Angeles
  • Memphis
  • Miami
  • Milwaukee
  • Nairobi
  • Nashville
  • New York
  • Norfolk
  • Philadelphia
  • Phoenix
  • Portland
  • Scottsdale
  • Seattle
  • St. Louis
  • Syracuse
  • Washington
Trial Identifier:

NCT04377555 ML42071

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The study plans to enroll approximately 150 participants (75 AA and 75 HA) with 50 participants enrolled in a CSF sub-study.

      Genentech, Inc. Sponsor
      Phase 4 Phase
      NCT04377555 , ML42071 Trial Identifier
      Ocrelizumab Treatments
      Multiple Sclerosis, Relapsing Condition
      Official Title

      An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With Ocrelizumab

      Eligibility Criteria

      All Gender
      ≥18 Years & ≤ 65 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Diagnosis of RMS with Expanded Disability Status Scale (EDSS) 0-5.5 at enrollment
      • Participants who self-identify as Black or African American or Hispanic/Latino American
      • Treatment-naïve or initiating first or second switch from receiving treatment with certain disease modifying therapies (DMTs) including interferon or glatiramer acetate or dimethyl fumarate (DMF); or siponimod; or fingolimod; or diroximel fumarate; or teriflunomide; or ozanimod; or natalizumab
      • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for 6 months after the final dose of ocrelizumab
      • Neurologically stable for at least 30 days prior to randomization and baseline assessments
      Exclusion Criteria
      • Diagnosis of secondary progressive MS without relapses for at least 1 year (nonactive or inactive SPMS)
      • Primary Progressive Multiple Sclerosis (PPMS)
      • Participants with contraindication to gadolinium based contrast agent for MRI and participants who cannot tolerate MRI procedure
      • Infection Related
      • Cancer Related
      • Pregnant or lactating, or intending to become pregnant during the study
      • Other Medical Conditions
      • Known presence or history of other neurologic disorders
      • Vaccinations: Receipt of a live vaccine, or attenuated, or inactivated / component vaccine within 6 weeks prior to first administration of ocrelizumab
      • Laboratory: abnormalities or findings at screening

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now